Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H (2019) Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health 11:287–299. https://doi.org/10.2147/IJWH.S197604

Article  PubMed  PubMed Central  Google Scholar 

Lheureux S, Braunstein M, Oza AM (2019) Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 69(4):280–304. https://doi.org/10.3322/caac.21559

Article  PubMed  Google Scholar 

Ledermann JA, Raja FA, Fotopoulou C, et al (2013) Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi24–32. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24078660

Benedetti Panici P, Di Donato V, Fischetti M, Casorelli A, Perniola G, Musella A et al (2015) Predictors of post-operative morbidity after cytoreduction for advanced ovarian cancer: Analysis and management of complications in upper abdominal surgery. Gynecol Oncol. 137(3):406–11. https://doi.org/10.1016/j.ygyno.2015.03.043

Article  PubMed  Google Scholar 

Gerestein CG, Damhuis RA, Burger CW, Kooi GS (2009) Post-operative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: asystematic review. Gynecol Oncol 114(3):523–7. https://doi.org/10.1016/j.ygyno.2009.03.011

Article  PubMed  Google Scholar 

Gao B, Lindemann K, Anderson L, Fereday S, Hung J, Alsop K et al (2016) Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DD, DeFazio A Serous ovarian and primary peritoneal cancers: a comparative analysis of clinicopathological features, molecular subtypes and treatment outcome. Gynecol Oncol 142(3):458–64. https://doi.org/10.1016/j.ygyno.2016.06.023

Article  CAS  PubMed  Google Scholar 

Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V et al (2020) Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 30(11):1657–1664. https://doi.org/10.1136/ijgc-2020-001640

Article  PubMed  Google Scholar 

Wright JD, Herzog TJ, Neugut AI, Burke WM, Lu YS, Lewin SN et al (2012) Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer. Obstet Gynecol 120(4):871–81. https://doi.org/10.1097/AOG.0b013e31826981de

Article  PubMed  Google Scholar 

Alexander M et al (2017) Timely initiation of chemotherapy: a systematic literature review of six priority cancers - results and recommendations for clinical practice. Intern Med J 47:16–34. https://doi.org/10.1111/imj.13190

Article  CAS  PubMed  Google Scholar 

Lydiksen L, Jensen-Fangel S, Blaakaer J (2014) Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer? Gynecol Oncol 133(3):454–459. https://doi.org/10.1016/j.ygyno.2014.04.004

Article  CAS  PubMed  Google Scholar 

Liu XD, Liu Y, Gong TT, Guo JY, Wang YN, Wang L, Wu QJ, Jiao YS (2018) Prognostic influence of the time interval between surgery and chemotherapy in epithelial ovarian cancer. J Cancer 9(22):4172–4178. https://doi.org/10.7150/jca.27409

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seagle BL, Butler SK, Strohl AE, Nieves-Neira W, Shahabi S (2017) Chemotherapy delay after primary debulking surgery for ovarian cancer. Gynecol Oncol 144(2):260–265. https://doi.org/10.1016/j.ygyno.2016.11.022

Article  PubMed  Google Scholar 

Timmermans M, van der Aa MA, Lalisang RI, Witteveen PO, Van de Vijver KK, Kruitwagen RF et al (2018) Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer. Gynecol Oncol 150(3):446–450. https://doi.org/10.1016/j.ygyno.2018.07.004

Article  CAS  PubMed  Google Scholar 

Aletti GD, Long HJ, Podratz KC, Cliby WA (2007) Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer? Gynecol Oncol 104:212–6. https://doi.org/10.1016/j.ygyno.2006.07.045

Article  PubMed  Google Scholar 

Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, Van Gorp T, Trillsch F, Mahner S, Ulmer H, Grimm C, Castillo-Tong DC, Zeillinger R, Zeimet AG, Vergote I (2013) The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecol Oncol 131(1):15–20. https://doi.org/10.1016/j.ygyno.2013.07.086

Article  CAS  PubMed  Google Scholar 

Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213. https://doi.org/10.1097/01.sla.0000133083.54934.ae

Article  PubMed  PubMed Central  Google Scholar 

Ananthan VA (2021) Modified Kuppuswamy scale for socioeconomic status of the Indian family- update based on new CPI (IW) series from September 2020. J Family Med Prim Care 10(5):2048–2049. https://doi.org/10.4103/jfmpc.jfmpc_2242_20

Article  PubMed  PubMed Central  Google Scholar 

Nishikimi K, Tate S, Kato K, Matsuoka A, Shozu M (2020) Well-trained gynecologic oncologists can perform bowel resection and upper abdominal surgery safely. J Gynecol Oncol 31(1):e3. https://doi.org/10.3802/jgo.2020.31.e3

Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A et al (2006) Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 98(3):172–80. https://doi.org/10.1093/jnci/djj019

Article  PubMed  Google Scholar 

Rottmann M, Burges A, Mahner S et al (2017) Cancer of the ovary, fallopian tube, and peritoneum: a population-based comparison of the prognostic factors and outcomes. J Cancer Res Clin Oncol 143(9):1833–1844. https://doi.org/10.1007/s00432-017-2422-6

Article  PubMed  Google Scholar 

McGuire WP et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334(1):1–6. https://doi.org/10.1056/NEJM199601043340101

Article  CAS  PubMed  Google Scholar 

Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F (2017) Treatment of recurrent ovarian cancer. Ann Oncol 28(suppl_8):viii51–viii56. https://doi.org/10.1093/annonc/mdx441

Gerestein CG, Nieuwenhuyzen-de Boer GM, Eijkemans MJ, Kooi GS, Burger CW (2010) Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer. Eur J Cancer 46(1):102–9. https://doi.org/10.1016/j.ejca.2009.10.017

Article  CAS  PubMed  Google Scholar 

Obermair A, Hagenauer S, Tamandl D, Clayton RD, Nicklin JL, Perrin LC et al (2001) Safety and efficacy of low anterior en bloc resection as part of cytoreductive surgery for patients with ovarian cancer. Gynecol Oncol 83:115–120. https://doi.org/10.1006/gyno.2001.6353

Article  CAS  PubMed  Google Scholar 

Ataseven B, du Bois A, Reinthaller A et al (2015) Preoperative serum albumin is associated with post- operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery. Gynecol Oncol 138(3):560–565. https://doi.org/10.1016/j.ygyno.2015.07.005

Article  CAS  PubMed  Google Scholar 

Llueca A, Serra A, Maiocchi K, Delgado K, Jativa R, Gomez L et al (2019) Predictive model for major complications after extensive abdominal surgery in primary advanced ovarian cancer. Int J Womens Health 7(11):161–167. https://doi.org/10.2147/IJWH.S190493

Article  Google Scholar 

Chi DS, Zivanovic O, Levinson KL, Kolev V, Huh J, Dottino J et al (2010) The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol 119:38–42. https://doi.org/10.1016/j.ygyno.2010.05.031

Article  PubMed  Google Scholar 

Khuri SF, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ (2005) Participants in the VA National Surgical Quality Improvement Program. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg 242(3):326–41. https://doi.org/10.1097/01.sla.0000179621.33268.83

Wright JD, Herzog TJ, Siddiq Z, Arend R, Neugut AI, Burke WM et al (2012) Failure to rescue as a source of variation in hospital mortality for ovarian cancer. J Clin Oncol 30(32):3976–82. https://doi.org/10.1200/JCO.2012.43.2906

Article  PubMed  Google Scholar 

Wright J, Doan T, McBride R, Jacobson J, Hershman D (2008) Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. Br J Cancer 98(7):1197–203. https://doi.org/10.1038/sj.bjc.6604298

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahner S, Eulenburg C, Staehle A, Wegscheider K, Reuss A, Pujade-Lauraine E et al (2013) Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. Eur J Cancer 49(1):142–149.